Patents by Inventor Andre Trouet
Andre Trouet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240123074Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.Type: ApplicationFiled: April 28, 2023Publication date: April 18, 2024Inventor: André TROUET
-
Publication number: 20200215196Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prod-rug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.Type: ApplicationFiled: January 24, 2020Publication date: July 9, 2020Inventor: André TROUET
-
Patent number: 10583194Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.Type: GrantFiled: September 17, 2018Date of Patent: March 10, 2020Assignee: COBIORES NVInventor: André Trouet
-
Publication number: 20190175740Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.Type: ApplicationFiled: September 17, 2018Publication date: June 13, 2019Inventor: André TROUET
-
Patent number: 10076576Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.Type: GrantFiled: December 27, 2013Date of Patent: September 18, 2018Assignee: LIFE SCIENCES RESEARCH PARTNERS VZWInventor: André Trouet
-
Publication number: 20160058880Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.Type: ApplicationFiled: December 27, 2013Publication date: March 3, 2016Inventor: André TROUET
-
Patent number: 8034787Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.Type: GrantFiled: August 14, 2008Date of Patent: October 11, 2011Assignee: Medarex, Inc.Inventors: Vincent Dubois, Ann Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
-
Patent number: 7951772Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.Type: GrantFiled: June 10, 2008Date of Patent: May 31, 2011Assignees: La Region Wallonne, Universite Catholique de LouvainInventors: Andre Trouet, Roger Baurain
-
Patent number: 7893023Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.Type: GrantFiled: June 11, 2008Date of Patent: February 22, 2011Assignee: Medarex, Inc.Inventors: Andre Trouet, Vincent Dubois, Alexandre Passioukov
-
Patent number: 7816317Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.Type: GrantFiled: March 27, 2007Date of Patent: October 19, 2010Assignee: Medarex, Inc.Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
-
Publication number: 20090220529Abstract: This invention relates to the field of antibody-drug conjugates, and more particularly antibody-drug conjugates that are intended for the treatment and/or diagnosis of diseases such as tumors and/or inflammatory reactions.Type: ApplicationFiled: March 10, 2006Publication date: September 3, 2009Applicant: Diatos, S.A.Inventors: Andre Trouet, Vincent Dubois
-
Publication number: 20090137494Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.Type: ApplicationFiled: June 10, 2008Publication date: May 28, 2009Applicants: La Region Wallonne, Universite Catholique de LouvainInventors: Andre Trouet, Roger Baurain
-
Publication number: 20090110753Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.Type: ApplicationFiled: August 14, 2008Publication date: April 30, 2009Applicant: MEDAREX, INC.Inventors: Vincent Dubois, Anne Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
-
Publication number: 20090076176Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.Type: ApplicationFiled: June 11, 2008Publication date: March 19, 2009Applicant: MEDAREX, INC.Inventors: Andre Trouet, Vincent Dubois, Alexandre Passioukov
-
Patent number: 7425541Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.Type: GrantFiled: June 11, 2001Date of Patent: September 16, 2008Assignee: Medarex, Inc.Inventors: Vincent Dubois, Ann Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey Yarranton
-
Patent number: 7402556Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.Type: GrantFiled: August 23, 2001Date of Patent: July 22, 2008Assignee: Medarex, Inc.Inventors: André Trouet, Vincent Dubois, Alexandre Passioukov
-
Patent number: 7390629Abstract: Methods of screening and identifying tumor-activated prodrug forms of therapeutic agents are described.Type: GrantFiled: March 8, 2006Date of Patent: June 24, 2008Assignees: La Region Wallonne, Universite Catholique de LouvainInventors: Andre Trouet, Roger Baurain
-
Publication number: 20070275903Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.Type: ApplicationFiled: March 27, 2007Publication date: November 29, 2007Applicant: MEDAREX, INC.Inventors: Christopher Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas Lobl, Matthew Nieder, Lesley Pickford, Andre Trouet, Geoffrey Yarranton
-
Patent number: 7214663Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.Type: GrantFiled: June 11, 2001Date of Patent: May 8, 2007Assignee: Medarex, Inc.Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
-
Publication number: 20060281897Abstract: This invention is directed to a modified form of a prodrug. A typical form of prodrug according to the invention comprises a bulky group, a spacer, a structure that can be cleaved at or near the target cells and a therapeutic agent or a marker, whereby the spacer allows or facilitates the cleavage of the cleavable structure.Type: ApplicationFiled: February 22, 2006Publication date: December 14, 2006Inventors: Andre Trouet, Vincent Dubois